Last Price
1.62
Today's Change
+0.07 (4.51%)
Day's Change
1.51 - 1.62
Trading Volume
21,680
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. David J. Arthur M.B.A. Mr. David J. Arthur M.B.A.
Full Time Employees: 2 2
IPO Date: 2015-01-29 2015-01-29
CIK: 0001615219 0001615219
ISIN: US79400X3052 US79400X3052
CUSIP: 79400X107 79400X107
Beta: 0.93 0.93
Last Dividend: 0.00 0.00
Dcf Diff: -0.17 -0.17
Dcf: 1.72 1.72
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.